# A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

> **NCT02334748** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis
- Hereditary Periodic Fevers

## Interventions

- **DRUG:** canakinumab

## Key facts

- **NCT ID:** NCT02334748
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-03
- **Primary completion:** 2018-08-31
- **Final completion:** 2018-08-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334748, "A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02334748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*